The use of live biotherapeutic products is a developing strategy to treat challenging diseases. Administration of one such drug, called VE303, could become successful against recurrent C. difficile infections.
Dysbiosis
Scientists analyzed the “collateral damage” of antibiotics on our gut microbiome and identified potential antidotes to protect our gut bacteria.
Our skin is teeming with microbes crucial to its health. However, one microbe is not always the skin’s friend.
Determining the causal link between diseases and microbiota is still a challenge in microbiota research. But animal models […]
micro-bites.org 